◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › Q › QURE

Uniqure NV (QURE) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-29

Uniqure NV (QURE) operates in the BIOTECHNOLOGY industry and is headquartered in Amsterdam, Netherlands with about 221 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, QURE reported $16M in revenue and ($199M) in net income.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.

Interactive charts & full statements → Open the QURE valuation workbench →

QURE Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$19M	$16M	$27M	$16M	$106M	$524M	$38M	$7M	$11M	$13M	$25M	$10M	$6M	$4M	—	—
Gross Profit	$4M	$14M	$9M	$2M	$103M	$499M	($85M)	$7M	($62M)	($54M)	$25M	$10M	($38M)	$3M	($13M)	—
Gross Margin %	22.8%	89.5%	32.4%	14.0%	96.9%	95.2%	-226.3%	100.0%	-547.5%	-414.3%	100.0%	93.8%	-664.9%	72.8%	—	—
Operating Income (EBIT)	($203M)	($188M)	($184M)	($283M)	($143M)	$311M	($125M)	($121M)	($88M)	($72M)	($72M)	($75M)	($41M)	($31M)	($19M)	($22M)
Operating Margin %	-1089.1%	-1166.8%	-679.6%	-1785.5%	-134.4%	59.3%	-334.3%	-1663.8%	-781.9%	-549.0%	-286.7%	-726.1%	-722.2%	-765.7%	—	—
Net Income	($252M)	($199M)	($240M)	($308M)	($127M)	$330M	($125M)	($124M)	($83M)	($80M)	($73M)	($78M)	($45M)	($37M)	($19M)	($22M)
Net Margin %	-1350.7%	-1236.0%	-883.4%	-1947.1%	-119.1%	62.9%	-333.3%	-1705.8%	-738.2%	-613.3%	-292.4%	-758.4%	-790.6%	-911.3%	—	—
EBITDA	($181M)	($117M)	($161M)	($253M)	($108M)	$319M	($127M)	($114M)	($74M)	($70M)	($66M)	($72M)	($46M)	($34M)	($18M)	($23M)
Earnings Per Share (EPS)	$-4.10	$-3.46	$-4.92	$-6.47	$-2.71	$7.04	$-2.81	$-3.11	$-2.34	$-2.98	$-2.93	$-3.54	$-2.63	$-2.10	$-1.11	$-1.27
Shares Outstanding (M)	66M	58M	49M	48M	47M	47M	44M	40M	36M	27M	25M	22M	17M	18M	18M	18M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

QURE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$6M	$4M	$6M	$4M	$5M	$2M	$5M	$2M
Gross Profit	($5M)	$3M	$2M	$3M	$5M	$1M	$5M	$1M
Gross Margin %	-78.0%	93.8%	38.9%	89.2%	87.5%	87.4%	88.1%	55.4%
Operating Income (EBIT)	($56M)	($44M)	($52M)	($51M)	($44M)	($39M)	($46M)	($40M)
Operating Margin %	-956.8%	-1242.8%	-936.8%	-1379.0%	-833.6%	-2510.0%	-877.8%	-1759.0%
Net Income	($81M)	($54M)	($37M)	($81M)	($38M)	($44M)	($73M)	($44M)
Net Margin %	-1387.8%	-1503.0%	-666.1%	-2175.9%	-716.8%	-2784.8%	-1403.2%	-1940.4%
EBITDA	($70M)	($36M)	($23M)	($52M)	($18M)	($24M)	($53M)	($25M)
Earnings Per Share (EPS)	$-1.22	$-0.85	$-0.64	$-1.38	$-0.69	$-0.82	$-1.50	$-0.91
Shares Outstanding (M)	66M	63M	58M	59M	55M	53M	49M	49M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

QURE Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($161M)	($178M)	($183M)	($146M)	($145M)	$288M	($135M)	($99M)	($76M)	($64M)	($72M)	$19M	($31M)	($6M)	($15M)	($22M)
Capital Expenditures (CapEx)	$1M	$0M	$3M	$7M	$18M	$17M	$9M	$7M	$4M	$6M	$17M	$9M	$23M	$8M	$1M	$0M
Free Cash Flow (FCF)	($162M)	($178M)	($186M)	($153M)	($163M)	$271M	($144M)	($105M)	($80M)	($70M)	($89M)	$9M	($54M)	($14M)	($16M)	($22M)
FCF Margin %	-866.5%	-1108.2%	-686.2%	-966.2%	-152.8%	51.6%	-384.7%	-1446.7%	-711.5%	-532.9%	-356.1%	90.8%	-951.1%	-344.0%	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

QURE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($29M)	($38M)	($78M)	($16M)	($40M)	($44M)	($53M)	($37M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$9M
Free Cash Flow (FCF)	($29M)	($38M)	($78M)	($16M)	($40M)	($44M)	($53M)	($45M)
FCF Margin %	-497.3%	-1077.6%	-1398.9%	-444.9%	-763.1%	-2822.3%	-1013.3%	-1979.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

QURE Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Assets	$985M	$825M	$557M	$832M	$705M	$809M	$340M	$449M	$274M	$209M	$190M	$265M	$116M	$54M	$7M	$8M	$30M
Cash & Cash Equivalents	$413M	$80M	$159M	$241M	$228M	$556M	$245M	$378M	$235M	$159M	$132M	$223M	$65M	$33M	$0M	$1M	$24M
Total Liabilities	$661M	$626M	$563M	$624M	$229M	$213M	$96M	$126M	$94M	$119M	$127M	$134M	$64M	$46M	$8M	$11M	$12M
Total Debt (Short + Long-Term)	$53M	$54M	$55M	$110M	$111M	$107M	$41M	$42M	$43M	$22M	$20M	$20M	$21M	$10M	$1M	$0M	$0M
Total Shareholders' Equity	$324M	$199M	($7M)	$208M	$476M	$596M	$244M	$323M	$180M	$90M	$64M	$131M	$52M	$8M	($1M)	($3M)	$18M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive QURE viewer.

Other Companies in BIOTECHNOLOGY

DYN · Dyne Therapeutics Inc — $3 billion
ARQT · Arcutis Biotherapeutics Inc — $3 billion
RCUS · Arcus Biosciences Inc — $3 billion
DNLI · Denali Therapeutics Inc — $3 billion
MBX · MBX Biosciences, Inc. Common Stock — $3 billion
CLDX · Celldex Therapeutics Inc — $3 billion
ZLAB · Zai Lab Ltd — $3 billion
PGEN · Precigen Inc — $3 billion

← QUMS All “Q” companies QUS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.